Search results

21 result(s) for

Home

Explore key efficacy and safety data, dosing information, and how to identify the right patients for CABENUVA (cabotegravir; rilpivirine). For US HCPs only.

Dosing

Learn more about CABENUVA (cabotegravir; rilpivirine) dosing & administration, including dosing frequency and planning patient visits. For US HCPs only.

Every-2-Month vs Once-Monthly CABENUVA

Explore safety data, including adverse events, for the ATLAS-2M CABENUVA (cabotegravir; rilpivirine) study. For US HCPs only.

Once-Monthly CABENUVA vs Daily Oral Therapy

Explore safety data, including adverse events and 96-week data, for the FLAIR CABENUVA (cabotegravir; rilpivirine) study. For US HCPs only.

CABENUVA vs BIKTARVY

Explore safety data, including adverse events, and the study design for a CABENUVA (cabotegravir; rilpivirine) head-to-head switch study. For US HCPs only.

Every-2-Month vs Once-Monthly CABENUVA

Explore efficacy data, the study design and baseline characteristics for the ATLAS-2M CABENUVA (cabotegravir; rilpivirine) study. For US HCPs only.

Once-Monthly CABENUVA vs Daily Oral Therapy

Explore key efficacy data, the study designs and baseline characteristics for the ATLAS & FLAIR CABENUVA (cabotegravir; rilpivirine) studies. For US HCPs only.

CABENUVA vs BIKTARVY

Explore efficacy data, the study design, and baseline characteristics for a CABENUVA (cabotegravir; rilpivirine) head-to-head switch study. For US HCPs only.

CBRWCNT230024